Metabolomic and nutrigenetic effects of folic acid supplementation and unmetabolized folic acid

叶酸补充剂和未代谢叶酸的代谢组学和营养遗传效应

• 批准号: 10224696
• 负责人: Mary Gamble
• 金额: $ 64.68万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10224696
• 关键词: Adverse effects; Bangladesh; Bayesian Modeling; Beverages; Biochemical Pathway; Carbon; Clinical; Collaborations; Country; DHFR gene; Data; Development; Dietary Intervention; Disease; Dose; Enzymes; Etiology; Folic Acid; Folic Acid Deficiency; Food; Funding; Future; Genes; Genotype; Goals; Gold; Health; Hormones; Human; Individual; Intake; Intervention Studies; Laws; Link; Lipids; Measurement; Measures; Mediating; Metabolic; Metabolic Diseases; Metabolic Pathway; Metabolism; Methyltransferase; Neural Tube Defects; Nutrient; Observational Study; Outcome; Pathway interactions; Pattern; Pattern Recognition; Phenotype; Placebos; Plasma; Policies; Population; Prevention; Process; Proteins; Randomized; Reaction; Recommendation; Research; Research Design; Resolution; Role; S-Adenosylmethionine; Safety; Sample Size; Sampling; Serum; Systems Biology; Testing; Time; Uncertainty; United States National Institutes of Health; Walkers; biobank; body system; data repository; design; double-blind placebo controlled trial; folic acid supplementation; fortification; genetic variant; genome-wide; metabolic phenotype; metabolome; metabolomics; methyl group; multiple omics; novel; nucleotide metabolism; nutrition related genetics; programs; randomized placebo controlled trial; response; small molecule; systematic review; trial design

Folate is a key regulator of one-carbon metabolism (OCM), a biochemical pathway that provides methyl groups for numerous reactions including hundreds of essential methyltransferase enzymes. Food fortification with folic acid (FA), a synthetic inactive form of folate more stable than the natural form in food (5-methyltetrahydrofolate (5mTHF)), is mandated by law in 87 countries, including the US. People vary in their ability to metabolize FA to 5mTHF, resulting in unmetabolized FA (UMFA), which is present in serum of >95% of the US population. While adequate folate intake is essential for human health, the widespread presence of UMFA in serum has raised questions regarding potential unanticipated adverse effects. Expert panels systematically reviewing the safety of high FA intake concluded there is strong evidence on the benefits of FA, e.g. for neural tube defect prevention, but uncertainty for non-NTD outcomes. Many feel that there is a critical need to identify alterations in metabolites and metabolic pathways associated with high FA intake. The metabolome offers a robust approach to do so as it integrates meaningful changes in a broad spectrum of key regulatory processes. The goal of this proposal is to leverage a wealth of data and banked samples from a recently completed randomized, double-blind, placebo-controlled trial (RCT) of FA supplementation (FACT, n=610) in Bangladesh. Unlike the US, Bangladesh is a FA-naïve population, as foods are not fortified with FA. We propose to incorporate new studies that will use novel high-resolution metabolomics (HRM). Untargeted metabolomics is the quantitative measurement of small-molecule metabolites that captures an unbiased snap-shot of the activity of all metabolically active organ systems involved in the development of almost all metabolic disorders. The FACT study design includes supplementation with FA (400 or 800 µg/d x 12 or 24 weeks), and a “wash-out” period following FA cessation. This study design permits us to identify and validate novel metabolites and pathways altered by FA supplementation (Aim 1) and UMFA (Aim 2) and to determine the stability or reversibility of those effects over time. In collaboration with Dr. Walker, leader of the high-resolution metabolomics facility at Mt. Sinai, we will combine FACT’s rigorous RCT approach – the gold standard design to determine causality – with HRM that interrogates greater than 80% of metabolic pathways. We will test the hypotheses that FA supplementation and/or UMFA influence unanticipated downstream metabolites and pathways, and identify those that may be linked to health outcomes. In Aim 3, in collaboration with geneticist, Dr. Pierce, we will evaluate how gene variants influence the effects of FA supplementation and UMFA on metabolomic outcomes. In Aim 4, with Dr. Kioumourtzoglou, we will use novel pattern recognition and hierarchical approaches to identify specific metabolic patterns that are impacted by FA supplementation and/or UMFA. The findings of this study may inform policy decisions regarding FA fortification programs and the forms and doses of folate sold in over-the-counter supplements and used in popular beverage products.

叶酸是一碳代谢（OCM）的关键调节剂，OCM是一种为许多反应提供甲基的生化途径，包括数百种必需的甲基转移酶。食品强化叶酸（FA）是一种合成的非活性形式的叶酸，比食品中的天然形式（5-甲基四氢叶酸（5 mTHF））更稳定，在87个国家（包括美国）的法律中强制执行。人们将FA代谢为5 mTHF的能力各不相同，导致未代谢的FA（UMFA）存在于>95%的美国人口的血清中。虽然足够的叶酸摄入量对人类健康至关重要，但血清中普遍存在的UMFA引起了关于潜在的非预期不良反应的问题。专家小组系统地审查了高FA摄入量的安全性，得出的结论是，有强有力的证据表明FA的益处，例如预防神经管缺陷，但非NTD结果的不确定性。许多人认为，有一个关键的需要，以确定改变代谢产物和代谢途径与高FA摄入量。代谢组学提供了一种强大的方法来做到这一点，因为它整合了广泛的关键调控过程中的有意义的变化。本提案的目标是利用孟加拉国最近完成的FA补充剂随机、双盲、安慰剂对照试验（RCT）（FACT，n=610）的大量数据和库存样本。与美国不同，孟加拉国是一个FA幼稚的人口，因为食物没有强化FA。我们建议纳入新的研究，将使用新的高分辨率代谢组学（HRM）。非靶向代谢组学是对小分子代谢物的定量测量，其捕获几乎所有代谢紊乱发展中涉及的所有代谢活性器官系统的活性的无偏快照。FACT研究设计包括补充FA（400或800 µg/d × 12或24周），以及FA停药后的“洗脱”期。这项研究设计使我们能够识别和验证FA补充（目标1）和UMFA（目标2）改变的新代谢物和途径，并确定这些作用随时间的稳定性或可逆性。在与步行者博士，在山高分辨率代谢组学设施的领导人合作。西奈半岛，我们将结合联合收割机事实的严格随机对照试验的方法-黄金标准设计，以确定因果关系-与人力资源管理，询问超过80%的代谢途径。我们将测试FA补充和/或UMFA影响意料之外的下游代谢物和途径的假设，并确定那些可能与健康结果有关的假设。在目标3中，我们将与遗传学家Pierce博士合作，评估基因变异如何影响FA补充剂和UMFA对代谢组学结果的影响。在目标4中，我们将与Kioumourtzoglou博士一起使用新的模式识别和分层方法来识别受FA补充和/或UMFA影响的特定代谢模式。这项研究的结果可能会告知有关FA强化计划和非处方补充剂中销售的叶酸形式和剂量以及流行饮料产品中使用的叶酸的政策决定。